TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02304991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liquid Peanut Extract
Description: 5000mcg/ml peanut protein

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Glycerin SLIT
Description: pure glycerinated saline solution with caramel coloring to match color
Study: NCT00939107

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: McKenzie exercises
Description: McKenzie exercises according to the principles of Mechanical Diagnosis and Therapy
Study: NCT00769795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMC-A12
Description: IMC-A12 will be administered every 2 weeks for a total of 6 doses at 10 mg/kg per dose. The last dose of IMC-A12 will be at least 2 weeks prior to prostatectomy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: Bicalutamide 50 mg daily orally for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin
Description: 10.8 mg subcutaneous once
Study: NCT01746446

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Care team
Description: Provides additional support to patients, family, and friends.
Study: NCT02132897

Intervention type: DRUG
Group type: OTHER
Intervention: Auration CR Tablets 400 Single Dose-Tegretol CR 400 Single Dose
Description: Carbamazepine CR Tablets 400 milligrams is given orally with 250 mL of water at room temperature.

Intervention type: DRUG
Group type: OTHER
Intervention: Tegretol CR 400 Single Dose-Auration CR 400 Single Dose
Description: Auration CR 400 milligrams Single Dose is given orally with 250 mL of water at room temperature.
Study: NCT05754476

Intervention type: OTHER
Intervention: Low-dose GBCA levels
Description: MRI examinations for patients at two dose levels: low-dose (10% or 25%）can be chosen.
Study: NCT03745235

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stress reduction program based on mindfulness
Description: a two and a half hour session per week for 8 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: venipunctures
Description: 1 dry tube of 5 ml and 5 heparinized tubes of 6 ml taken at inclusion, at 3 months and at 12 months

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: venipunctures
Description: 1 dry tube of 5 ml and 5 heparinized tubes of 6 ml taken at inclusion, at 3 months and at 12 months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: psychometric questionnaires
Description: * Cohen PSS' perceived stress scale~* Beck's anxiety and depression questionnaires~* Watson's affectivity questionnaire, positive affect and negative affect schedule~* optimism questionnaire, Life Orientation Test LOT-R by Sheier and Carver~* IN-OUT DASQ dispositional affective style questionnaire

Intervention type: OTHER
Group type: OTHER
Intervention: psychometric questionnaires
Description: * Cohen PSS' perceived stress scale~* Beck's anxiety and depression questionnaires~* Watson's affectivity questionnaire, positive affect and negative affect schedule~* optimism questionnaire, Life Orientation Test LOT-R by Sheier and Carver~* IN-OUT DASQ dispositional affective style questionnaire
Study: NCT00290589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intramuscular methylprednisolone acetate
Description: Intramuscular methylprednisolone acetate 160mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline intramuscular injection
Study: NCT03234400

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Dapivirine Vaginal Ring, 25 mg
Description: Vaginal Ring containing 25 mg dapivirine

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Dapivirine Vaginal Ring, 100 mg
Description: Vaginal Ring containing 100 mg dapivirine

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Dapivirine Vaginal Ring, 200 mg
Description: Vaginal Ring containing 200 mg dapivirine
Study: NCT04950842

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JB-101
Description: induced T cell with suppressive function
Study: NCT01599702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron Isomaltoside 1000
Description: 1500-3000mg IV depending on HB level, sex and body weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron Isomaltoside 1000
Description: 1500-3000mg IV depending on HB level, sex and body weight
Study: NCT02166229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Divalproex sodium
Study: NCT01691053

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone
Description: 50mg once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04811001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: TAGRISSO 40 mg film-coated tablets TAGRISSO 80 mg film-coated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: TAGRISSO 40 mg film-coated tablets TAGRISSO 80 mg film-coated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacomitinib
Description: Vizimpro 15 mg film-coated tablets Vizimpro 30 mg film-coated tablets Vizimpro 45 mg film-coated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacomitinib
Description: Vizimpro 15 mg film-coated tablets Vizimpro 30 mg film-coated tablets Vizimpro 45 mg film-coated tablets
Study: NCT00779311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib
Description: Sorafenib will be administered daily starting day 1 at 200mg QOD at Dose Level 1; 200mg/day at Dose Level 2; 200mg BID (5 days on/ 2 days off) at Dose Level 3; 200mg BID at Dose Level 4; and 400mg BID at Dose Level 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Bevacizumab will be administered as 5mg/kg IV on Day 1 of each treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6 regimen
Description: The mFOLFOX6 regimen will be administered on Day 1 of each treatment cycle. This regimen consists of oxaliplatin 85 mg/m2 IV given over 2 hours, leucovorin 400 mg/m2 IV given over 2 hours, and fluorouracil 400 mg/m2 IV bolus, followed by fluorouracil 1200 mg/m2 per day for 2 days continuous infusion.
Study: NCT00118911

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT)
Description: Participants are provided with education about ADHD and instruction in organizational skills, reducing distractibility, and adaptive thinking.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation techniques and education about ADHD
Description: Participants are provided with education about ADHD, instruction in relaxation techniques, and support in applying relaxation techniques to ADHD symptoms.
Study: NCT03159819

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CAR-CLD18 T Cells
Description: Dose escalation will be applied in this study.
Study: NCT01867866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-102
Description: 35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifluridine
Description: 35 mg/m2, orally, single dose
Study: NCT03909672

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cupping Therapy
Description: application of cupping therapy with two acrylic type 1 cups (4.5 cm internal diameter, Dong Yang ® brand) with a distance of 3 cm each cup, parallel to the L1 to L5 vertebrae bilaterally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cupping Therapy
Description: application of cupping therapy with two acrylic type 1 cups (4.5 cm internal diameter, Dong Yang ® brand) with a distance of 3 cm each cup, parallel to the L1 to L5 vertebrae bilaterally
Study: NCT03330041

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fast absorbing gut suture
Description: Fast absorbing surgical gut suture is a strand of collagenous material

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fast absorbing gut suture
Description: Fast absorbing surgical gut suture is a strand of collagenous material
Study: NCT03790384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin
Description: Patients receive BCG induction treatment according to the standard protocol (an instillation once a week for six weeks) with ImmuCyst (81 mg Connaught strain BCG) with a 40 mg mitomycin instillation the day before .
Study: NCT01259635

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biofeedback auditory stimulation
Description: Whenever freezing episodes occures, a metronom sound will be heard.
Study: NCT03606148

Intervention type: DIAGNOSTIC_TEST
Intervention: SurePathTM
Description: In the liquid-phase cytology, a fine-aspirated sample is immediately inserted into a container containing a commercially available preservative solution without a separate slide-smearing procedure and immediately after the fine-needle aspiration.

Intervention type: DIAGNOSTIC_TEST
Intervention: SurePathTM
Description: In the liquid-phase cytology, a fine-aspirated sample is immediately inserted into a container containing a commercially available preservative solution without a separate slide-smearing procedure and immediately after the fine-needle aspiration.
Study: NCT03395223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylene Blue
Description: Administration of Methylene Blue to treat acquired methaemoglobinaemia
Study: NCT02452268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NIZ985
Description: Subcutaneous administration of hetIL-15 three times a week for two consecutive weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDR001
Description: • PDR001 is a human monoclonal antibody (MAb) administered day 1 of each cycle
Study: NCT01379170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Euthyrox (levothyroxine)
Description: A dose of 25 μg per day of Euthyrox® will be administered orally during the first week and will be increased to 50 μg per day during the second week and to 75-100 μg per day in the third week depending on TSH, free T4 and T3 concentrations monitored throughout the treatment period. Patients will be instructed to take Euthyrox® after an overnight fast, 30 min before breakfast in the morning daily. After 3 months, free T4 and total T3 concentration must be in the normal range (free T4: 8.0-26 pmol/l, T4: 60-140 nmol/l and T3 1.2 - 3.4 nmol/l) and TSH 0.4-2.5 mU/l.
Study: NCT02755142

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Gliolan

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Gliolan

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Gliolan
Study: NCT03876145

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Minimal ovarian stimulation
Description: After obtaining informed consent to participate in the study, the subjects will be randomly divided into the following 4 groups: The group of minimal ovarian stimulation with rec-FSH or HMG. The group of mild ovarian stimulation with rec-FSH or HMG. In all 4 experimental groups, after reaching at least three follicles the size of 12 millimeters (mm), daily administration of 0.25 milligram (mg) Cetrotide (antagonist GnRH) will be started and after reaching at least three follicles the size of 17 mm, 500 microgram Ovitrelle (recombinant Human curionic gonadotropin) will be prescribed. 36 hours later, ovulation process will be done. On the day of Ovitrelle administration, serum levels of estradiol and progesterone will be also evaluated. Based on the patient's condition and the quality of obtained oocytes and embryos, 2 embryos will be transferred.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Minimal ovarian stimulation
Description: After obtaining informed consent to participate in the study, the subjects will be randomly divided into the following 4 groups: The group of minimal ovarian stimulation with rec-FSH or HMG. The group of mild ovarian stimulation with rec-FSH or HMG. In all 4 experimental groups, after reaching at least three follicles the size of 12 millimeters (mm), daily administration of 0.25 milligram (mg) Cetrotide (antagonist GnRH) will be started and after reaching at least three follicles the size of 17 mm, 500 microgram Ovitrelle (recombinant Human curionic gonadotropin) will be prescribed. 36 hours later, ovulation process will be done. On the day of Ovitrelle administration, serum levels of estradiol and progesterone will be also evaluated. Based on the patient's condition and the quality of obtained oocytes and embryos, 2 embryos will be transferred.
Study: NCT01080144

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Critical flicker frequency procedure
Description: After TIPS, patients will be followed during one year and the psychometric test and Critical flicker frequency procedure will be performed every 3 months
Study: NCT04763590

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: This study focuses on patients who are on a mechanical ventilator and who have been medically cleared to come off of it. The purpose of the study is to learn more about the possible influence of cognitive behavioral therapy in helping patients who are having some trouble getting off of the ventilator. Cognitive behavioral therapy is a highly effective intervention for anxiety and the investigators are evaluating whether cognitive behavioral therapy might be helpful in cases where it is difficult to come off of the ventilator.~Cognitive behavioral therapy is experimental for mechanical ventilation assistance as no research to date has evaluated whether it might be helpful.
Study: NCT01862432

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immediate skin-to-skin
Description: The newborn is place on his mother's chest, immediately (in the first minute of life), in order to allow complete skin-to-skin contact.
Study: NCT02448316

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopic surgery
Description: Through 2 portals profound for the fascia plantaris (deep-fascial) lateral and medial a heel-spur will be resected and the medial half of the fascia is released from its attachment to the calcaneus.~A mikroskopic X-ray sensitive pearle (Tantalum-pearle) will be inserted in the fascia in the proximal end of the distal part of the remaining fascia for measuring distance (resorbtion).~Three weeks after operation, the patients are instructed to start a specific training program. Training is supervised every third week by a physiotherapist (week 3,6,9,12 after operation), and daily training is carried out at home. Sutures are removed after 10 days,

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolon
Description: 1ml methylprednisolon is mixed with 1ml of Lidocain and injected underneath the plantar fascia as close to the medial attachment on calcaneus as possible

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidokaine
Description: 1ml methylprednisolon is mixed with 1ml of Lidocain and injected underneath the plantar fascia as close to the medial attachment on calcaneus as possible

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Training
Description: the patient is instructed in reduction in impact. strength training 3 times weekly and stretching exercises daily are recommended.
Study: NCT03048942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Description: 3 weekly cyctotoxic chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Weekly cyctotoxic chemotherapy
Study: NCT03997929

Intervention type: DIAGNOSTIC_TEST
Intervention: 1.3 BETA D GLUCAN
Description: dosage of 1.3 BETA D GLUCAN in the peritoneal fluid obtained during surgery with the β-glucan test (Fujifilm Wako Chemicals, Osaka, Japan)

Intervention type: DIAGNOSTIC_TEST
Intervention: 1.3 BETA D GLUCAN
Description: dosage of 1.3 BETA D GLUCAN in the peritoneal fluid obtained during surgery with the β-glucan test (Fujifilm Wako Chemicals, Osaka, Japan)
Study: NCT02899741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3
Description: 1000mg every day for 90 days
Study: NCT00540306

Intervention type: DEVICE
Intervention: Diffuse Optical Spectroscopy
Description: Changes in physiological and optical properties in healthy pre-menopausal breast tissue during the menstrual cycle using Diffuse Optical Spectroscopy
Study: NCT04024072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brinzolamide 1% ophthalmic suspension
Description: Test product

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azopt 1% Ophthalmic Suspension
Description: Reference product
Study: NCT03673696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC74647PA Capsule
Description: Capsule administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC74647PA Capsule
Description: Capsule administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC74647PA Capsule
Description: Capsule administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC74647PA Capsule
Description: Capsule administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC74647PA Capsule
Description: Capsule administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC74647PA Capsule
Description: Capsule administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC74647PA Capsule
Description: Capsule administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC74647PA Capsule
Description: Capsule administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC74647PA Capsule
Description: Capsule administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Matching Placebo Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Matching Placebo Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Matching Placebo Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Matching Placebo Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Matching Placebo Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Matching Placebo Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Matching Placebo Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Matching Placebo Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Matching Placebo Capsule
Study: NCT00769808

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bausch & Lomb 217z Excimer Laser
Description: LASIK correction of myopia and myopic astigmatism
Study: NCT03438578

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Efficacy Safety Score monitoring
Description: According to data gathered from ESS and monitoring, the patients will receive needed care.
Study: NCT02157246

Intervention type: OTHER
Group type: OTHER
Intervention: Pimonidazole

Intervention type: OTHER
Group type: OTHER
Intervention: F-MISO PET

Intervention type: OTHER
Group type: OTHER
Intervention: F-MISO PET

Intervention type: OTHER
Group type: OTHER
Intervention: pCT

Intervention type: OTHER
Group type: OTHER
Intervention: pCT

Intervention type: OTHER
Group type: OTHER
Intervention: Functional MRI

Intervention type: OTHER
Group type: OTHER
Intervention: Functional MRI

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Biopsy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Biopsy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood sample

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood sample
Study: NCT03212807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Investigational Medicinal Product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Investigational Medicinal Product
Study: NCT04066946

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microcurrent therapy
Description: Micro current therapy is a therapy to treat humans / animals using electric current with amperages flowing in the μA range. The device offers 2 treatment methods: manual treatment, which requires manual input corresponding to the mentioned parameters, and automatic treatment which, depending on the clinical picture and the currently measured resistance between the electrodes, allows the device to automatically change the mentioned parameters. For this study the investigators use an automatic treatment with predefined settings. This automatic programme consists of a variation of 20 different frequency settings during 17 minutes. This programme is repeated one time which leads to a total treatment time of 34 minutes. The intensity setting for the treatment is between 200 and 350 µA. The treatment is applied 5x per week in the first 6 weeks. The treatment is stopped after six weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Standard of Care consists of:~During the first two weeks:~* Histoacryl glue to close the surgical incisions.~* Suture strips to keep the wound closed.~* Isobetadine Dermicum as anti-septic treatment~* Dry wound dressings during the first 2 weeks.~* Tubigrip~From two weeks until three months:~• Hydration with hydrating crème 2x per day (not within 4 hours before microcurrent treatment.~From three months onwards:~• Silicone gel sheet.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Standard of Care consists of:~During the first two weeks:~* Histoacryl glue to close the surgical incisions.~* Suture strips to keep the wound closed.~* Isobetadine Dermicum as anti-septic treatment~* Dry wound dressings during the first 2 weeks.~* Tubigrip~From two weeks until three months:~• Hydration with hydrating crème 2x per day (not within 4 hours before microcurrent treatment.~From three months onwards:~• Silicone gel sheet.
Study: NCT04035265

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Blood test
Description: Carpus and fingers of non-dominating hand MRI with gadolinium contrast

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood test
Description: Carpus and fingers of non-dominating hand MRI with gadolinium contrast

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood test
Description: Carpus and fingers of non-dominating hand MRI with gadolinium contrast

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood test
Description: Carpus and fingers of non-dominating hand MRI with gadolinium contrast